Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Graham D. Hogg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7143-0695; OpenAlex author ID A5053159872; NIH RePORTER profile ID 15108620. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers, 1 grant · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adp3978↗
  2. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1080/2162402x.2024.2320411↗
  3. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  4. Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-0946↗
  5. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1039226↗
  6. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗
  7. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
  8. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Co-author DOI 10.1126/scitranslmed.aau9240↗

Grants 1

  1. Harnessing Dendritic Cells as a Novel Therapy in Pancreatic Ductal Adenocarcinoma F30CA254087↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William G. Hawkins · 8 shared papers, 2019–2025 · strength 1.10
  2. David G DeNardo · 8 shared papers, 2019–2025 · strength 1.10
  3. Ryan C Fields · 7 shared papers, 2019–2025 · strength 0.95
  4. C. Alston James · 4 shared papers, 2021–2024 · strength 0.60
  5. Varintra E. Lander · 4 shared papers, 2020–2025 · strength 0.56
  6. Chong Zuo · 5 shared papers, 2019–2023 · strength 0.56
  7. John M. Baer · 3 shared papers, 2020–2023 · strength 0.38
  8. Liang‐I Kang · 2 shared papers, 2023–2025 · strength 0.34
  9. Roheena Z. Panni · 2 shared papers, 2019–2025 · strength 0.27
  10. Hui Chin Peng · 2 shared papers, 2021–2022 · strength 0.26
  11. William E. Gillanders · 2 shared papers, 2021–2022 · strength 0.26
  12. Yongwoo David Seo · 1 shared paper, 2024 · strength 0.20
  13. Venu Gopal Pillarisetty · 1 shared paper, 2024 · strength 0.20
  14. Vikram S. Pothuri · 1 shared paper, 2024 · strength 0.20
  15. Blake E. Sells · 1 shared paper, 2025 · strength 0.19
  16. Alyssa G. Weinstein · 1 shared paper, 2025 · strength 0.19
  17. Tiantian Liu · 1 shared paper, 2025 · strength 0.19
  18. Julie Kristina Schwarz · 2 shared papers, 2019–2020 · strength 0.17
  19. Samarth Hegde · 2 shared papers, 2019–2020 · strength 0.17
  20. Usman Younis Panni · 1 shared paper, 2023 · strength 0.15
  21. Jad I. Belle · 1 shared paper, 2023 · strength 0.14
  22. Paarth B. Dodhiawala · 1 shared paper, 2023 · strength 0.14
  23. Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14
  24. Kian‐Huat Lim · 1 shared paper, 2023 · strength 0.14
  25. Li Ding · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.